FDA Approval Process for Wearable Medical Devices: The 2025 Guide

• The FDA Approval Snapshot
• Understanding Risk: Class I, II, and III
• The 3 Critical Pathways: 510(k), De Novo, & PMA
• The ‘General Wellness’ Exemption Explained
• AI & The Future of Software as a Medical Device (SaMD)
• Real-World Examples: FDA-Cleared Tech
• Frequently Asked Questions

Bringing a wearable medical device to market is not just an engineering challenge; it is a regulatory labyrinth. The distinction between a consumer gadget and a medical device often comes down to a single phrase in your marketing materials: the Intended Use. If your smart ring claims to “promote relaxation,” it is likely a wellness tool. If it claims to “diagnose sleep apnea,” it is a medical device subject to the Code of Federal Regulations (CFR).

Below is a comprehensive guide to navigating the FDA’s regulatory frameworks, from classification to clearance, specifically tailored for the booming wearable health tech sector.

Understanding Risk: Class I, II, and III

The FDA does not regulate products based on their technology, but rather on their risk to the patient if the device fails. This risk-based classification system is the foundation of your entire go-to-market strategy.

Class I: Low Risk (General Controls)

Class I devices have the lowest impact on patient health. For wearable developers, this category often includes simple mechanical aids or basic software that doesn’t drive clinical decisions. Approximately 95% of Class I devices are exempt from premarket notification. They still require registration and listing with the FDA, but you generally do not need to wait for approval to sell them.

Class II: Moderate Risk (Special Controls)

This is where the majority of sophisticated health wearables live (e.g., smartwatches with ECG capabilities, connected blood pressure cuffs). If a Class II device fails, it could cause harm, but likely not death. These devices almost always require 510(k) clearance. You must demonstrate that your technology is safe and effective by comparing it to a device that is already on the market.

Class III: High Risk (Premarket Approval)

Class III is reserved for devices that sustain life, are implanted, or present a potential unreasonable risk of illness or injury. In the wearable space, this is rare but possible for devices that automatically deliver therapy (like an automated insulin delivery system driven by a wearable sensor). These require a Premarket Approval (PMA), the FDA’s most stringent regulatory category, demanding extensive clinical trials.

The 3 Critical Pathways: 510(k), De Novo, & PMA

Once you know your class, you must select the correct submission pathway. Choosing the wrong one can cost millions in delays.

1. The 510(k) Clearance

This is the most common route for wearables. The goal is Substantial Equivalence. You do not necessarily need to prove your device works from scratch; you only need to prove it is as safe and effective as a “predicate device.” For example, if you develop a new optical heart rate monitor, you would compare its data accuracy against a previously cleared heart rate monitor. If the data correlates within an acceptable margin of error, you gain clearance.

2. The De Novo Request

What if your wearable is low-to-moderate risk (Class I or II) but is so innovative that there is no existing predicate device to compare it to? You cannot use the 510(k) pathway. Instead, you submit a De Novo request. This creates a new classification regulation for your device type. Once granted, your device becomes the new predicate for future competitors.

3. Premarket Approval (PMA)

For Class III devices, the standard is “reasonable assurance of safety and effectiveness.” This requires independent scientific evidence, usually in the form of multi-phase clinical trials. Unlike the 510(k), which results in “clearance,” a PMA results in actual FDA “approval.” It is a multi-year, multi-million dollar process.

The ‘General Wellness’ Exemption Explained

Not every health wearable needs the FDA. Under the FDA’s Digital Health Center of Excellence guidance, the agency exercises “enforcement discretion” for General Wellness products. These are devices that:

• Relate to maintaining or encouraging a general state of health (e.g., weight management, sleep tracking).
• Do NOT make references to specific diseases or conditions.

The Trap: The moment you claim your device “treats anxiety” or “detects arrhythmias,” you cross the line from General Wellness to Medical Device. Smart companies often launch with wellness claims to generate revenue while simultaneously gathering clinical data for a future 510(k) submission to unlock medical claims.

AI & The Future of Software as a Medical Device (SaMD)

According to recent reports, the FDA is actively refining its approach to AI-enabled devices. The traditional model—where a device is “locked” after approval—does not work for AI that learns and evolves. The FDA’s new Total Product Life Cycle (TPLC) approach aims to allow for iterative updates to algorithms without requiring a new submission for every minor software patch, provided the changes do not alter the intended use or introduce new risks.

This shift is critical for startups using Machine Learning. The goal is to move from a “static” regulation model to a “performance-based” monitoring model, where the manufacturer monitors the AI’s performance in the real world (Post-Market Surveillance) and reports anomalies.

Real-World Examples: FDA-Cleared Tech

To understand the bar for “Clearance,” look at these products that successfully navigated the 510(k) or De Novo process.

Check Price on Amazon

The AliveCor KardiaMobile is a prime example of a Class II device. It transforms a smartphone into a clinical-grade EKG. By proving substantial equivalence to traditional hospital EKGs, AliveCor secured FDA clearance to detect Atrial Fibrillation, Bradycardia, and Tachycardia—claims that a standard fitness tracker cannot legally make.

Check Price on Amazon

The Owlet Dream Sock represents the shift from wellness to medical. Initially marketed as a consumer product, Owlet pursued and received FDA clearance to provide “live pulse rate and oxygen notifications” for infants. This transition required rigorous testing to prove the sensor’s accuracy matched hospital pulse oximeters.

Frequently Asked Questions